Whether you are a new T1D Family, a TrialNet participant, a healthcare provider, or a researcher — you'll find resources here.
We’re here to help you after a new T1D diagnosis. Get answers to frequently asked questions and learn about clinical studies testing ways to maintain insulin production.
While you wait for screening results, get answers to your questions, find out about next steps, and learn more about TrialNet’s Pathway to Prevention.
Your T1D families are important to you. Learn how easy it is to connect your patients with world-class T1D research.
Desert Senita Community Health Center
410 N. Macate St, Ajo, AZ 85321
Claudia Vogel, MD
10561 Jeffrey Street, Henderson, NV 89052
Horizon View Medical Center - Pediatric Endocrinology
6850 N Durango D, Las Vegas, NV 89149
Valley Childrens Hospital
9300 Valley Children's Place, Madera, CA 93636
Banner Health Cardon Childrens Medical Center
1400 S. Dobson Rd, Mesa, AZ 85202
Childrens Hospital of Orange County
1201 West La Veta, Orange, CA 92868
16601 N 40th St, Phoenix, AZ 85032
Pediatric Endocrinology and Diabetes Clinic
7010 East Chauncey Lane, Phoenix, AZ 85054
Pediatric Endocrinology of Phoenix
15600 N Black Canyon Hwy, Phoenix, AZ 85053
University of California-San Diego
3020 Childrens Way MC 5105, San Diego, CA 92123
Sansum Diabetes Research Institute
2219 Bath Street, Santa Barbara, CA 93105
Kaiser Permanente Santa Clara
710 Lawrence Expwy, Pediatrics Endocrinology, Santa Clara, CA 95051
Beaver Medical Group Yucaipa Valley
33758 Yucaipa Blvd, Yucaipa, CA 92399
If you have a relative with T1D, you’re in a unique position to help us learn more about the disease and how to stop it. The first step is to sign up for Pathway to Prevention screening to determine your risk of developing T1D.
TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 to stage 2) and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression.
We tested the drug teplizumab to see if it could delay or prevent progression of early stage T1D (stage 2) and prevent clinical diagnosis (stage 3). In earlier studies in people newly diagnosed (stage 3), teplizumab helped to prolong insulin production.
We are testing the drug hydroxychloroquine (HCQ) to see if it can delay or prevent early stage T1D (stage 1) from progressing to abnormal glucose tolerance (stage 2) and ultimately prevent clinical diagnosis (stage 3). HCQ is already used to reduce symptoms and progression of other autoimmune diseases, such as rheumatoid arthritis and lupus. This is the first study to see if it can prevent or delay T1D.
Once your study ends, we're still here for you. Participant monitoring and continued involvement helps us learn more about T1D.